Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 6,250 Shares

Posted by Francis Steltz on Jun 17th, 2026

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) insider Samira Shaikhly sold 6,250 shares of Septerna stock in a transaction on Friday, June 12th. The stock was sold at an average price of $35.08, for a total transaction of $219,250.00. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at $27,818.44. This represents a 88.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total transaction of $171,699.55.
On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Stock Performance

NASDAQ SEPN opened at $35.17 on Wednesday. Septerna, Inc. has a 52-week low of $9.85 and a 52-week high of $37.01. The company has a market capitalization of $1.59 billion, a P/E ratio of -43.42 and a beta of 2.39. The company has a fifty day moving average of $27.39 and a 200-day moving average of $26.88.

Septerna (NASDAQ:SEPN – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The company had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. As a group, analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Septerna

Hedge funds have recently modified their holdings of the company. Group One Trading LLC increased its position in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new position in shares of Septerna in the fourth quarter valued at about $35,000. Russell Investments Group Ltd. purchased a new position in shares of Septerna in the third quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Septerna in the fourth quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Septerna in the fourth quarter valued at about $61,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on SEPN shares. Guggenheim started coverage on shares of Septerna in a research report on Thursday, June 11th. They issued a “buy” rating and a $52.00 target price on the stock. Wells Fargo & Company lifted their target price on shares of Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Septerna in a research report on Wednesday, May 13th. Stifel Nicolaus started coverage on shares of Septerna in a research report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price on the stock. Finally, Truist Financial lifted their target price on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Septerna currently has an average rating of “Moderate Buy” and an average target price of $45.78.

Check Out Our Latest Stock Analysis on SEPN

Septerna Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.